Current Research Studies

SC-N188: Views and Outcomes with Immune effector Cell therapy (VOICE)

SC-N188: VOICE

  • Condition(s): Melanoma, Skin, Bones and Joints, Cervix, Anus, Urinary Bladder, Pancreas, Rectum, Lymphoid Leukemia, Small Intestine, Breast, Mycosis Fungoides, Thyroid, Multiple Myeloma, Other Digestive Organ, Colon, Hodgkin's Lymphoma, Lip, Oral Cavity and Pharynx, Non-malignant Disease, Other Respiratory and Intrathoracic Organs, Other Female Genital, Kidney, Leukemia, other, Myeloid and Monocytic Leukemia, Soft Tissue, Prostate, Ill-Defined Sites, Other Skin, Corpus Uteri, Other Hematopoietic, Kaposi's Sarcoma, Esophagus, Brain and Nervous System, Stomach, Larynx, Unknown Sites, Other Urinary, Ovary, Liver, Lung, Non-Hodgkin's Lymphoma, Eye and Orbit, Other Male Genital, Other Endocrine System
  • Phase: N/A
  • Clinicaltrials.gov ID: NA

What is the goal of the study?

This is a longitudinal study of patient-reported outcomes of children, adolescents, and young adults receiving immune effector cell (e.g., CAR-T) therapy at Seattle Children's Hospital. Participants will be asked to complete surveys at 7 longitudinal timepoints around immune effector cell therapy related to physical symptoms and psychosocial functioning. Data from this study will provide us with patient and caregiver perspectives of experiences with this novel therapy. Findings may help inform how we counsel patients receiving immune effector cell therapy in the future, and also lead to innovative clinician-facing symptom monitoring interventions.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team: